Sickle cell disease (SCD) is a severe hemoglobinopathy, characterized by recurrent vaso-occlusive crises (VOC) causing intense pain and frequent hospitalizations in adult patients. Current French and British guidelines recommend rapid administration of strong opioids, primarily through patient-controlled analgesia (PCA), as the reference treatment for hospitalized patients experiencing VOC. However, opioid use is associated with dose-dependent adverse effects, including nausea, constipation, pruritus, sedation, and hypoventilation, the latter representing a risk factor for acute chest syndrome.
The hypothesis underlying this study is that multimodal analgesia-combining morphine PCA with co-analgesics such as paracetamol-can significantly reduce morphine consumption during hospitalization compared to opioid-only analgesia, while maintaining effective pain control. Although several co-analgesic agents (paracetamol, NSAIDs, nefopam, tramadol, ketamine) are recommended by expert guidelines, including those from the American Society of Hematology (2020) and French recommendations (2025), the level of evidence supporting their use in adult sickle cell patients remains low or non-existent for most agents, with no randomized controlled trials available for nefopam, tramadol, or ketamine.
Using an adaptive platform design, this trial aims to compare multiple analgesic strategies against standard opioid-based care, generating higher-quality evidence to optimize pain management protocols for adult patients experiencing VOC

开始日期2026-10-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

CTIS2026-526719-13-00

/ Not yet recruiting临床4期

POISON – Perioperative Safety and Effective Opioid Dosing in Chronic Opioid Use – a Randomized Clinical Study

开始日期2026-09-01

申办/合作机构

Region Hovedstadens Apotek

100 项与盐酸吗啡水合物相关的临床结果

登录后查看更多信息

100 项与盐酸吗啡水合物相关的转化医学

登录后查看更多信息

100 项与盐酸吗啡水合物相关的专利（医药）

登录后查看更多信息

23,084

项与盐酸吗啡水合物相关的文献（医药）

2026-11-01·European Journal of Hospital Pharmacy

ICU Y-site compatibility at standardised infusion concentrations: method-stratified synthesis and practical chart

Article

作者: Garreta Fontelles, Gemma ; Liron Sanchez, Tomas ; Maqueda Palau, Monica ; Barbado Monge, Maria del Carmen ; Padilla Castaño, Helena ; Lopez Lopez-Cepero, Marta ; Martorell Puigserver, Clara

BACKGROUND:

Adults who are critically ill frequently require multiple intravenous infusions through limited vascular access, making Y-site co-infusion unavoidable. However, much of the primary compatibility literature uses concentrations, diluents and visual-only methods that do not reflect contemporary intensive care unit (ICU) practice, risking false reassurance at the bedside.

OBJECTIVE:

To create an ICU-specific, concentration-matched Y-site compatibility chart aligned to standardised infusion concentrations and to identify compatible, conditional, incompatible and no-data drug-pairs.

METHODS:

We performed a PRISMA (preferred reporting items for systematic reviews and meta-analyses) guided, method-stratified synthesis (1970-2025) of in-vitro Y-site evidence from PubMed, Trissel's and Micromedex. Classifications privileged instrumented endpoints (pH, turbidimetry, sub-visible particles, high-performance liquid chromatography) over visual inspection. Drug-drug pairs were mapped to our tertiary adult ICU formulary; medicines with an established ward standard were deemed ICU standardised.

OUTCOMES:

compatible (C), compatible in saline only (Csf), conditional (concentration/diluent dependent; applied only when at least one medicine was ICU standardised), incompatible-physical (Ie/Ip/It) or chemical (Iq)-or no data (ND).

RESULTS:

Among 4465 mapped drug-pairs, 43.94% were compatible (C 42.37%, Csf 1.57%); 2.53% were conditional; 8.24% were incompatible-predominantly physical; and 45.29% lacked eligible evidence. High-risk clusters included lipid emulsions (eg, propofol, clevidipine), extreme-pH agents (eg, amiodarone, furosemide), phenytoin and calcium salts. For morphine hydrochloride, evidence was sparse (76% ND, 21% compatible, 1% conditional, 2% incompatible). Amiodarone exemplified concentration non-concordance; with an ICU concentration of 15 mg/mL, 34% of amiodarone drug-pairs had compatibility that was concentration dependent.

CONCLUSIONS:

At standardised ICU concentrations, fewer than half of potential Y-site pairings are unequivocally compatible and nearly half have no concentration-matched data. A conservative, method-stratified framework anchored to exact concentration and diluent mitigates risk and exposes evidence gaps. Applying a conservative, method-stratified framework anchored to exact concentration and diluent mitigates risk while revealing priority evidence gaps-especially for lipid emulsions, calcium-containing solutions, extreme-pH drugs and opioids. Embedding the chart within the electronic prescribing and medicines administration (EPMA) system can deliver checks, standardise line allocation, reduce uncertain Y-site mixing and prioritise dedicated lumens for high-risk agents.

2026-08-01·Fujita medical journal

Evaluation of renal function in a patient with terminal rectal cancer who developed morphine hydrochloride-induced respiratory depression.

Article

作者: Futamura, Akihiko ; Usui, Masanobu ; Inagaki, Takahiko ; Uekuzu, Yoshihiro

A challenge in patients with terminal cancer is that serum creatinine-based estimates of renal function often deviate from true renal function because cachexia-related loss of muscle mass leads to abnormally low serum creatinine levels. Serum cystatin C is a useful marker of renal function in patients with decreased muscle mass; however, there are limited data on its use in patients with terminal cancer. In this study, we present a detailed assessment of renal function, incorporating muscle mass measurement by bioelectrical impedance analysis, in a patient with terminal rectal cancer who developed respiratory depression while receiving a stable dose of morphine hydrochloride injections.

2026-07-01·INTERNATIONAL JOURNAL OF DRUG POLICY

Effect of the COVID-19 pandemic on initiations of opioid agonist therapy in Ontario: A population-based interrupted time series analysis

Article

作者: Barnett-Tapia, Carolina ; Bayoumi, Ahmed M ; Fairbairn, Nadia ; Gomes, Tara ; Raboud, Janet ; Young, Samantha ; Dodd, Zoë

BACKGROUND:

Maintaining access to opioid agonist therapy (OAT) was a key concern at the COVID-19 pandemic onset. Consequently, Ontario introduced guidance for changes to OAT delivery, including relaxed take-home dosing and expanded virtual care. We examined how the pandemic influenced OAT initiation trends.

METHODS:

We conducted a population-based, retrospective interrupted time series analysis using linked administrative health data from March 2018 to January 2022 in Ontario, Canada. OAT initiations were defined as new (no OAT prescribed in the preceding two years) prescriptions for methadone, buprenorphine/naloxone, or slow-release oral morphine. Weekly initiation trends were compared before and during two pandemic periods defined by provincial emergency declarations. Analyses were stratified by medication type and sex.

RESULTS:

We identified 31,866 new OAT initiations. Immediately after the pandemic began, initiations declined significantly (-36.7/week; 95% CI: -53.3 to -20.1), then gradually returned toward baseline. Overall initiation volumes during the pandemic were not clearly different from pre-pandemic levels, although estimates were imprecise. However, prescribing patterns shifted: we estimate that methadone initiations increased by 2321 (95% CI: 1600 to 3043), while buprenorphine/naloxone initiations declined by 2009 (95% CI: -2783 to -1235) as a result of the pandemic. Sex-stratified trends were consistent with overall findings.

CONCLUSIONS:

The pandemic led to a temporary drop in OAT initiations but no long-term decline. A shift toward methadone suggests changing preferences among prescribers and patients, potentially driven by updated guidance and rising drug toxicity. These findings support the need for flexible, low-barrier OAT delivery models that can adapt to public health emergencies and evolving unregulated drug supply risks.

项与盐酸吗啡水合物相关的新闻（医药）

2026-10-08

·蒲公英Ouryao

药典委公示7个化药标准草案，涉及替米沙坦、盐酸吗啡系列

转自：国家药典委编辑：水晶 10月8日，国家药监局公示了7个化药国家药品标准草案，涉及替米沙坦系列3个品种和盐酸吗啡系列4个品种。公示期至2027年1月6日。替米沙坦系列替米沙坦：现行标准为《中国药典》2025年版二部，美国药典USP2025、欧洲药典EP11.0均收载。拟定标准主要修订有关物质项。替米沙坦片：现行国家标准为WS1-(X-081)-2011Z，美国药典USP2025、英国药典BP2024均收载。拟定标准修订性状、有关物质、含量测定、贮藏，并增订含量均匀度检查项。替米沙坦胶囊：目前无国家标准，企业执行各自注册标准。拟定标准包括性状、鉴别、有关物质、含量均匀度、溶出度、其他检查、含量测定、类别、规格、贮藏等项目。盐酸吗啡系列盐酸吗啡：现行标准为《中国药典》2025年版二部，欧洲药典EP11、英国药典BP2025、日本药局方JP18收载。拟定标准修订有关物质项，并增加各已知杂质的化学结构和化学名。盐酸吗啡片：现行标准为《中国药典》2025年版二部，日本药局方JP17收载。拟定标准修订性状、规格、鉴别、有关物质、含量均匀度、溶出度、含量测定等项目。盐酸吗啡注射液：现行标准为《中国药典》2025年版二部，日本药局方JP17收载。拟定标准修订鉴别、有关物质、细菌内毒素、含量测定等项目。盐酸吗啡缓释片：现行标准为《中国药典》2025年版二部。拟定标准增订有关物质项，并修订鉴别、含量均匀度、含量测定等项目。

2026-09-17

·微信

【市场】28款新药遴选进院，独家品种成爆款

精彩内容近日，攀枝花市中心医院公告称，拟遴选28款新药进院以满足临床用药需求。其中，独家品种（含剂型独家，下同）占比超50%，不乏注射用重组人TNK组织型纤溶酶原激活剂、艾米替诺福韦片等2025年在中国公立医疗机构终端销售额超10亿元的畅销药，以及包醛氧淀粉胶囊等2026H1销售额增速达三位数的潜力品种。 28款拟遴选进院的新药包含4款医保甲类药、21款医保乙类药和3款非医保药；从剂型上看，注射剂为主力军，占据11个席位；药品类型方面，化药、生物药各有21个和7个。拟遴选进院新药来源：攀枝花市中心医院，米内网整理注：带*为独家品种注射用重组人TNK组织型纤溶酶原激活剂用于急性心肌梗死患者的溶栓治疗，目前国内仅石药集团拥有生产批文。在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端，该药2025年拿下创新高的超11亿元，同比增长159.65%；2026H1继续以33.77%的增速保持增长，首度摘下酶类（化+生）产品TOP1桂冠。近年来中国公立医疗机构终端注射用重组人TNK组织型纤溶酶原激活剂销售趋势（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局艾米替诺福韦片为翰森制药的独家1类创新药，用于治疗慢性乙肝成人患者。米内网数据显示，该药2021年经谈判纳入医保目录后市场放量明显，2023-2026H1在中国公立医疗机构终端销售额增速均达两位数及以上；其中2025年首次突破10亿元大关，2026H1同比增长19.17%，蝉联核苷及核苷酸逆转录酶抑制剂产品格局首位。 2026H1中国公立医疗机构终端核苷及核苷酸逆转录酶抑制剂产品格局来源：米内网中国公立医疗机构药品终端竞争格局此外，拟遴选进院的新药还包括：治疗高胆固醇血症的注射用瑞卡西单抗、用于儿童生长缓慢的金培生长激素注射液、治疗重度癌痛的盐酸吗啡缓释片等独家品种，以及注射用重组人脑利钠肽等2025年在中国公立医疗机构终端销售额超30亿元的畅销药，包醛氧淀粉胶囊、英克司兰钠注射液等2026H1销售额增速达三位数的潜力品种。资料来源：米内网数据库、攀枝花市中心医院注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至9月17日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。

2026-09-04

·米内网

【市场】28款新药拟进院，多个超10亿重磅在列

精彩内容日前，绵阳市妇幼保健院发布公示，拟引进28款新药以满足临床用药需求，“中化生”领域均有涉及，包括双环醇片、地舒单抗注射液等多款2025年在中国公立医疗机构终端销售额超10亿元的畅销药，以及连花清咳片、盐酸吗啡缓释片等独家品种（含剂型独家，下同）。拟引进新药包含3款医保甲类药、23款医保乙类药和2款非医保药；药品类型方面，化药、生物药、中成药各有20个、7个和1个；按治疗大类统计，消化系统及代谢药为主力军，占据7个席位。 28款拟进院新药中，不乏双环醇片、地舒单抗注射液等2025年在中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端销售额超10亿元的畅销药，以及连花清咳片、盐酸吗啡缓释片等独家品种。拟进院新药来源：绵阳市妇幼保健院，米内网整理注：带*为独家品种双环醇片由北京协和药厂开发并获批上市，用于慢性肝炎所致的氨基转移酶升高等，是我国首个具有国际自主知识产权的肝炎治疗1类化学新药。在中国公立医疗机构终端，该药近年来销售额逐年攀升，2025年拿下创新高的超15亿元，2026Q1同比增长20.22%，已连续多年稳居胆、肝疾病治疗药（化+生）产品前三。 2026Q1中国公立医疗机构终端胆、肝疾病治疗药（化+生）产品格局来源：米内网中国公立医疗机构药品终端竞争格局地舒单抗注射液用于骨折高风险的绝经后妇女的骨质疏松症，为国家医保乙类药品种。近年来，地舒单抗注射液在中国公立医疗机构终端销售额增长迅猛，2023年首破10亿元大关，2024-2025年先后超越20亿元和30亿元；2026Q1继续增长至近9亿元，市场在售的品牌中，齐鲁制药的该产品涨幅最大，达到111.27%。近年来中国公立医疗机构终端地舒单抗注射液销售趋势（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局连花清咳片为以岭药业的独家中成药，功能主治宣肺泄热、化痰止咳，用于急性气管-支气管炎痰热壅肺证引起的咳嗽、咳痰等，目前已纳入国家医保乙类药、OTC甲类药目录。2023-2025年该药在中国公立医疗机构终端销售规模均超1亿元，2026Q1收获近4000万元，在止咳祛痰平喘中成药品牌格局中攀升至TOP18。资料来源：米内网数据库、绵阳市妇幼保健院注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至9月4日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。

上市批准引进/卖出

100 项与盐酸吗啡水合物相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02271	盐酸吗啡水合物	N02AA01	DB00295

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
麻醉	日本	Sumitomo Pharma Co., Ltd.	1991-12-01
咳嗽	日本	Sumitomo Pharma Co., Ltd.	1991-12-01
腹泻	日本	Sumitomo Pharma Co., Ltd.	1991-12-01
疼痛	日本	Sumitomo Pharma Co., Ltd.	1991-12-01
癌症疼痛	日本	Sumitomo Pharma Co., Ltd.	1991-12-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性疼痛	临床1期	中国	西南药业股份有限公司	2022-08-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ATS2022	N/A	呼吸困难	-	Opioids	繭遞繭製遞壓選齋艱鏇(鹹壓醖糧鑰鏇醖鑰夢餘) = No major opioid-related adverse events were reported 夢廠夢願鏇鹹觸衊鑰齋 (鹽願齋廠憲齋顧積製鏇 )	-	2022-05-15
NCT02990910 (CTgov)	N/A	镇痛	280	Individualized opioid analgesia (Individualized Opioid Analgesia)	夢鹹壓願蓋夢築築繭選 = 衊膚蓋餘齋襯膚糧憲製範廠壓願遞壓築選遞遞 (鏇壓憲餘顧獵顧艱淵積, 觸鹽壓獵簾觸簾糧膚簾 ~ 壓壓構襯糧構膚願鑰範) 更多	-	2017-08-09
				conventional opioid analgesia (Conventional Opioid Analgesia)	夢鹹壓願蓋夢築築繭選 = 簾醖壓憲獵壓願醖壓壓範廠壓願遞壓築選遞遞 (鏇壓憲餘顧獵顧艱淵積, 淵餘夢鏇觸壓廠簾遞製 ~ 顧簾選餘鬱鏇醖蓋蓋醖) 更多
NCT02046772 (CTgov)	临床4期	痔疮	63	Bupivacaine low dose+Morphine Chloride (Bupivacaine + Morphine Chloride)	壓夢鹽願蓋積簾夢壓繭(遞夢憲夢鏇廠構鑰顧艱) = 淵選積艱淵願鬱鏇築鑰範觸蓋夢廠製廠膚積鑰 (築餘簾鏇餘窪糧壓窪壓, 1.8) 更多	-	2014-09-01
				Bupivacaine (Bupivacaine Standard Dose)	壓夢鹽願蓋積簾夢壓繭(遞夢憲夢鏇廠構鑰顧艱) = 醖願淵範憲鹽遞鏇廠醖範觸蓋夢廠製廠膚積鑰 (築餘簾鏇餘窪糧壓窪壓, 1.5) 更多
NCT00803114 (CTgov)	临床4期	疼痛	228	Preservative-free epidural morphine (Epidural Morphine)	鬱願鑰蓋壓壓築鑰糧艱 = 網鹽製鏇膚膚製構憲觸廠構製淵繭鹽構壓壓憲 (淵糧衊壓夢築獵膚遞糧, 築選鹹觸遞蓋鏇觸壓鹽 ~ 鹹鬱鹹窪構憲鹹鬱積艱) 更多	-	2008-12-05
				Placebo (Placebo)	鬱願鑰蓋壓壓築鑰糧艱 = 壓遞衊鏇鹹積鹽鏇夢醖廠構製淵繭鹽構壓壓憲 (淵糧衊壓夢築獵膚遞糧, 醖衊壓夢夢製顧餘餘觸 ~ 鹽襯願築構鏇築獵獵齋) 更多